Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.
Hoffmann
Thomas
T
Institute of Health Economics and Clinical Epidemiology, University of Cologne, Germany. thomas.hoffmann.th1@bayer-ag.de
Brunner
Helmut
H
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000191:economics*; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D017963:Azithromycin / Q000191:economics / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D017291:Clarithromycin / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D017048:Health Care Costs; D006801:Humans; D018803:Models, Economic; D015270:Mycobacterium avium-intracellulare Infection / Q000209:etiology / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D017828:Rifabutin / Q000191:economics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D011480:Protease Inhibitors; D017828:Rifabutin; D017963:Azithromycin; D017291:Clarithromycin